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Background: Partial nephrectomy is now the gold standard treatment for small renal tumors. Local recurrence is a
major problem after partial nephrectomy, and local recurrence in the remnant kidney after partial nephrectomy is
common.
Case presentation: A 77-year-old man underwent right partial nephrectomy for a T1 right renal cell carcinoma.
Microscopic examination revealed a clear cell renal carcinoma, grade 2, stage pT3a. Although the surgical margin
was negative, the carcinoma invaded the perirenal fat, and vascular involvement was strongly positive. Thirty
months after partial nephrectomy, an enhanced computed tomographic scan showed local recurrence of the renal
cell carcinoma extending into the inferior vena cava without renal mass. Hence, we performed right radical nephrectomy
and intracaval thrombectomy. Microscopic examination revealed a clear cell carcinoma grade 2, stage pT3a + b.
The patient is still alive with no evidence of recurrence 10 months post-procedure.
Conclusion: To our knowledge, local recurrence of renal cell carcinoma extending into the inferior vena cava
after partial nephrectomy has not been reported in the literature. Our case report emphasizes the importance of
strict surveillance of patients after partial nephrectomy, especially for those with renal cell carcinoma positive for
microvessel involvement.
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During the last decade, partial nephrectomy (PN) has
been accepted as an effective and safe alternative to rad-
ical nephrectomy (RN) for small renal tumors. Local re-
currence in the remnant kidney after PN is common,
being reported in 1%-3% of these patients.
Renal cell carcinoma (RCC) has a propensity to extend
into the inferior vena cava (IVC) through the renal vein,
as is seen in 4%-10% of these cases [1,2]. This involve-
ment is usually observed at the time of initial diagnosis;
local recurrence extending into the IVC after PN is ex-
ceedingly rare. We report a rare case of local recurrence
of RCC extending into the IVC after PN.* Correspondence: s00-001@nms.ac.jp
1Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku,
Tokyo 113-8603, Japan
Full list of author information is available at the end of the article
© 2014 Akatsuka et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Case presentation
A 77-year-old man was diagnosed with a right renal
tumor during a medical examination. Enhanced abdom-
inal computed tomography (CT) revealed a right renal
tumor (3.5 cm) at the upper renal pole (Figure 1). After
a diagnosis of right RCC (cT1aN0M0), right PN was per-
formed via a lateral retroperitoneal approach. Microscopic
examination revealed a clear cell carcinoma, grade 2, stage
pT3a. Although the surgical margin was microscopically
negative, perinephric fatty tissue invasion and microvessel
involvement (MVI) were positive (Figure 2). Hence, we
administered combination immunotherapy (interferon
(IFN)-α +meloxicam + cimetidine) as adjuvant therapy.
However, this therapy was discontinued after 2 months
because the patient became depressed. Because his serum
creatinine level was 1.53 mg/dl, we monitored his blood
test results and performed unenhanced CT of the chest
and abdomen every 4 months after surgery for the first
3 years.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Enhanced abdominal computed tomography revealed
a right renal tumor at the upper renal pole.
Figure 3 Enhanced computed tomography demonstrated an
enhanced tumor thrombus in the inferior vena cava extending
from the renal vein to the intrahepatic level.
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showed right renal vein swelling. Thereafter, contrast-
enhanced abdominal CT confirmed the presence of a
solid mass in the right renal vein extending into the
IVC. The tumor extended from the renal vein to below
the short hepatic vein without renal mass (Figure 3). No
distant metastases were observed by brain, chest, ab-
dominal and pelvic CT. The most feasible diagnosis at
this time was local recurrence of the RCC extending into
the IVC after PN (TNM staging classification: cT3bN0M0;
Classification of venous tumor thrombus 4-level system:
level I). We performed right RN and IVC thrombectomy
using a transabdominal approach. The tumor thrombus
extended from the renal vein to below the short hepaticFigure 2 Hematoxylin-eosin staining of the original partial
nephrectomy specimen, original magnification × 400,
demonstrated clear cell renal cell carcinoma with microvessel
invasion (arrow).vein and did not invade the vascular wall. Surgical time
was 667 min, blood loss was 3360 ml and specimen
weight was 223 g. Although there was slight recurrence
of the tumor at the renal sinus, there was no recur-
rence at the previous surgical site (Figure 4). MicroscopicFigure 4 The resected specimen included a tumor thrombus.
Large arrow: previous surgical location. Small arrows: tumor
recurrence at the renal sinus. Broken arrow: tumor thrombus.
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At 10 months after surgery, the patient is alive with no
evidence of disease recurrence or metastatic disease by
strict follow-up.
Discussion
Routine medical checkups have increased the detection
of small renal tumors and, hence, the necessity for PN.
Several investigators have reported that PN for small
renal tumors achieves equivalent oncologic outcomes
and better preservation of renal function compared with
RN [3,4]. Therefore, PN is now the gold standard treat-
ment for small renal tumors.
However, local recurrence is a major problem after
PN. A meta-analysis by American Urological Association
Education and Research found a local recurrence rate of
2.0% after laparotomy PN, and 1.6% after laparoscopic
PN [5].
Yossepowitch et al. reported clinical, pathological and
follow-up data on 1,344 patients who underwent 1,390
partial nephrectomies for kidney cancer [6]. In the re-
port, the overall 5- and 10-year rates of freedom from
local disease recurrence were 97% and 93%, respectively,
and the rates of freedom from metastatic progression
were 96% and 93%, respectively. Patients who undergo
PN need medium- and long-term follow-up, not only for
the possible development of distant metastases, but also
for the presence of local recurrence.
Bernhard et al. reported 26 (3.2%) ipsilateral recur-
rences among 809 PNs that occurred at a median time
of 27 (14.5–38.2) months after PN [7]. The mean age at
diagnosis was 59.3 ± 12.1 yr, and mean tumor size was
3.4 ± 1.9 cm. Twenty patients had purely local recur-
rence, whereas six had concurrent metastases. At the
end of follow-up, 18 (69%) patients were still alive, six
(23%) had died from cancer, and two (8%) had died from
other causes. The risk of ipsilateral RCC recurrence after
PN is significantly associated with tumor size > 4 cm,
tumor bilaterality (synchronous or asynchronous), and
positive surgical margin. Careful follow-up is recom-
mended in patients presenting with such characteristics.
In the present patient, the right renal tumor (3.5 cm)
was removed, and the surgical margin was microscopic-
ally negative.
Systemic progression of RCC depends on tumor access
to microvasculature [8]; hence, available data from sev-
eral studies on this topic have indicated a significant
prognostic value of MVI in such patients [9,10]. Dall’O-
glio et al. demonstrated the discriminator role of MVI as
a prognostic factor for RCC [11]. These investigators
found that 5-year disease-free rates were 87.1% for MVI-
negative cases vs. 32.6% for MVI-positive cases. In their
report, MVI was the most significant predictor of RCC
outcome compared with other variables such as tumorsize, Fuhrman grade and sarcomatoid degeneration. In
our patient, although the surgical margin was patho-
logically negative, MVI was positive. The site of tumor
recurrence was distinct from the site of previous surgical
resection. Considering the development of tumor recur-
rence at the renal sinus and extension into the IVC,
MVI was probably responsible for the recurrence pattern
in this patient. As far as we know, this is the first case of
local recurrence of RCC after PN extending into the
IVC. A probable cause of the rarity of advanced recur-
rence after PN is early discovery with strict follow-up.
Our experience suggests that there might potentially be
many other cases of recurrence extending into the IVC.
The National Comprehensive Cancer Network Guide-
lines [12] provide recommendations for follow-up after
PN. Although follow-up plans should be individualized
based on patient and tumor characteristics, one strategy
proposes chest and abdominal imaging every 6 months
for 2 years and annually for 5 years thereafter. As our pa-
tient’s renal function (BUN, 15.6 mg/ml; Cr, 1.53 mg/dl)
was poor and the PN specimen was strongly positive for
MVI, non-enhanced abdominal CT was performed every
4 months. Retrospective evaluation of non-enhanced
abdominal CT demonstrated swelling of the right renal
vein 20 months after PN. However, since the renal
shape was unaltered, we could not detect local recur-
rence at that time. As in our patient, it is necessary to
perform enhanced abdominal CT, MRI or abdominal
ultrasonography after PN in order to earlier detect re-
currence at the renal sinus with extension into the
IVC. Despite the significant likelihood of recurrence of
RCC in surgical margin- and MVI-positive cases, there
is no established evidence supporting adjuvant therapy
in these patients after surgery. Future clinical trials
should investigate the most efficacious adjuvant strat-
egy and agent. Our case report emphasizes the import-
ance of pre-operative imaging which should be best
performed with adequate modality and strict surveil-
lance of patients after PN, especially for those with
RCC positive for MVI.Conclusions
To the best of our knowledge, local recurrence extend-
ing into the IVC after PN has not previously been re-
ported in the literature. Our case report emphasizes the
importance of strict surveillance of patients after PN, es-
pecially for those with RCC positive for MVI.Consent
Written informed consent was obtained from the patient
for publication of this Case Report and accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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